insulin human
insulin human is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand name including MYXREDLIN. Available dosage forms: powder, injection, solution.
Drug Details
- Generic Name
- insulin human
- Brand Names
- MYXREDLIN
- Application Number
- BLA208157
- Sponsor
- Virtu Pharmako (Zhejiang) Co., Ltd.
- NDC Codes
- 7
- Dosage Forms
- POWDER, INJECTION, SOLUTION
- Routes
- INTRAVENOUS
- Active Ingredients
- INSULIN HUMAN
Indications and Usage
1 INDICATIONS AND USAGE AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA) [see Warnings and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking [see Warnings and Precautions ( 5.5 )].